INTRODUCTION
The use of dose-response models in health risk assessment of chemicals has received increasing attention in recent years.
Because of various limitations associated with the traditional procedure applied in this field of risk assessment, i.e., the NOAEL (no-observed-adverse-effect-level) approach, the benchmark dose (BMD) method has been proposed as an alternative (Allen et al., 1994; Barnes et al., 1995; Crump, 1984; Falk Filipsson et al., 2003; Gaylor et al., 1998; Sand et al., 2002; USEPA, 1995) . The BMD is defined as the dose of a chemical that is required to achieve a predetermined response of a toxicological effect. The BMD is estimated by fitting a dose-response model to data. An approximate lower confidence bound of the BMD is suggested to replace the NOAEL as a point of departure in the health risk assessment of chemical substances.
For continuous dose-response data a number of suggestions have been made for how to define the BMD. According to one of these procedures, sometimes referred to as the hybrid approach, the BMD is defined as corresponding to some increase in the probability of falling below (or exceeding) a cut-off value representing an ''adverse'' level of continuous response (Crump, 1995; Gaylor, and Slikker, 1990; Kodell, and West, 1993) . The hybrid concept allows the use of the same response definitions originally proposed for quantal data, suggesting a generalization of the BMD concept. However, the method requires decision making, not only with regard to the specification of the risk level-i.e., the benchmark response (BMR) associated with the BMD-but also concerning the cutoff value. It has been shown that the way of determining of the cut-off point (dependent or independent of the sample data) is crucial and dictates how the hybrid model depends on the variance . Moreover, the hybrid approach may not be straightforwardly used in the case of non-constant variance (Stiteler, and Swartout, 1991; West, and Kodell, 1993) , which is commonly observed for experimental data. Problems regarding the interpretation of the variance estimated in experimental studies have also been pointed out (Murrell et al., 1998; Slob, 2002) . Gaylor and Slikker (2004) recently discussed how individual variability and variability associated with measurement errors can be separated. However, such investigations may only be conducted for endpoints that allow a repeated measure design.
Other procedures for BMD calculations from continuous endpoints have focused on defining the BMD as a function of the dose-response model for the mean response. According to one of theses suggestions, the BMD has been presented as the dose that corresponds to a certain change in response relative to the background level. This approach was already introduced in the early stages of BMD modeling (Allen et al., 1994; Crump, 1984) . It was later argued more thoroughly and this response definition has been termed the critical effect size (CES) (Slob, 2002; Slob and Pieters, 1998) . The intention is that the CES should be given a value specific for the endpoint investigated and denoting a response change that is acceptable, or ''nonadverse,'' at the level of the individual organism (Slob, 2002; Slob and Pieters, 1998) . The BMD has also been suggested as the dose causing a percentage change in response relative to the magnitude, or size, of response (the difference between the maximum and minimum response level) (Kalliomaa et al., 1998; Murrell et al., 1998) . As with the hybrid approach, this definition has been argued to provide means of standardization; it has been suggested that biological responses may be considered to have some maximum or minimum response value, and endpoints may differ in terms of the resulting magnitude of response. Thus, defining the BMD as corresponding to a certain response change relative to this magnitude has been considered to result in BMDs that are comparable across different endpoints (Murrell et al., 1998) .
In this study a new procedure is presented of how to define the BMD for continuous experimental endpoints that have an S-shaped dose-response relationship. This approach concentrates on identifying a critical portion of the dose-response curve where the slope changes (accelerates) the most in the low-dose region. Such an exposure level resides within a ''transition dose range'' in which the sensitivity to chemical exposure may change noticeably. The consideration of dosedependent transitions of toxicity has been argued as a way to improve the risk assessment process, and it has been discussed that a dose within a transition dose region may be used as a replacement for the NOAEL or BMD (Slikker et al., 2004a) . Thus, the present study may be seen as a discussion of this latter feature, mostly from a methodological point of view. It is shown how a dose (BMD) within a transition dose region may be defined and estimated, and the article indirectly addresses the important issue of what response the BMD should correspond to. Also, the suggested procedure is contrasted to other methods of BMD analysis for continuous endpoints.
MATERIAL AND METHODS
Model fitting. The maximum likelihood approach was used in this work. For continuous dose-response data, which are normally distributed with mean, l(d i ), and non-constant variance, r 2 (d i ), over the dose levels, d i , the loglikelihood function, ln L, takes the form:
where N is the total number of animals; g is the number of dose groups; n i is the number of animals in the ith dose group; s 2 i is the unbiased sample variance in the ith dose group; and y i is the mean response observed in the ith dose group. The parameters defining the mean response, l(d i ), and the variance, r 2 (d i ), are estimated by the maximization of ln L. Different models were used for describing the mean response, l(d i ), which is discussed later, under Defining the benchmark dose for continuous data and Special cases associated with the approach. Also, constant and non-constant models for the variance were considered. The non-constant variance model was assumed to be a power function of the mean response, r 2 ðd i Þ ¼ k ½lðd i Þ q with parameters, k and q.
This model was used if it was preferred over the constant variance assumption according to a likelihood ratio test (with 1 degree of freedom).
Defining the benchmark dose for continuous data. The present study attempts to define the BMD as the dose where the slope of the S-shaped doseresponse relationship changes the most in the low-dose region. There are several models available to describe an S-shaped dose-response relationship. A very general model represents the so-called Richards function (Richards, 1959) , which considering the log-dose scale, x i , always has an S-shaped structure and may be written as
In this model, a is a parameter that describes the background; h is a parameter that describes the magnitude, or size, of the response (the difference between the maximum and minimum response level); j 1 is the location parameter; g is a parameter that describes the shape of the dose-response curve; m is a parameter that allows the curve to have asymmetrical properties; and x i represents log-dose (log d i ). For m ¼ 1, the Richards function coincides with the Hill function. As is shown in Figure 1 , the Hill function has symmetrical properties on the log-dose scale. For this special case, j 1 equals log ED 50 (which corresponds to the inflection point). Further, if m > 1, the Richard function becomes asymmetrical with more threshold-like characteristics in the low-dose region; if m < 1, it becomes skewed in the opposite direction (Fig. 1) .
FIG. 1.
Illustration of the Richards function. For all cases, a ¼ 60, h ¼ ÿ50, j 1 ¼ log 10, and, g ¼ 2. In Curves 1, 2, and 3 the m parameter is 0.5, 1, and 2, respectively. Considering the log-dose scale the Richards function is always S-shaped. For a value of m ¼ 1 the Richards function coincides with the Hill function, and has symmetrical properties (Curve 2). For m > 1 the model becomes asymmetrical with more threshold-like characteristics (Curve 3), and for m < 1 it becomes skewed in the other direction (Curve 1). 
respectively. The Richards function and its second and third derivative are illustrated in Figure 2 . As is shown, solving the roots of the third derivative gives the dose, x i , where the curvature of the dose-response relationship is the highest. The root of interest of the third derivative (Fig. 2) , here called log BMD T , where T denotes ''transition,'' is given by
The response, R, corresponding to the BMD may be expressed as a change relative to the magnitude, or size, of response (Murrell et al., 1998) :
Using this definition, it can be shown that the response, R T , associated with the BMD T equals
Apparently, under the Murrell et al. (1998) definition, the response at the BMD T can be nicely standardized; i.e., R T depends only on the m parameter. Thus, symmetrical/asymmetrical characteristics determine the response, R T , associated with the dose where the slope changes the most, i.e., symmetrical/ asymmetrical properties of the curve is mostly influenced by the m parameter in the Richards function. The log-dose scale was considered within the proposed definition of the critical dose level, BMD T . The log-scale was used because the S-shaped characteristics of the family of models considered (Richards function) generalize on this scale (Fig. 1) . However, it is important to realize the interpretation of slope on this scale. Consider an absolute increase in dose on log-scale from x1 to x2. On a ''normal'' scale, this means increasing a dose of 10 x1 to 10 x2 , which is achieved by multiplying 10 x1 by the factor, f ¼ 10
). When an increase in dose on the log-scale becomes very small, the factor, f, approaches 1 ( f ¼ 10 0 ). Thus, slope on the log-dose scale can be interpreted as the change in response that is obtained when dose (considering the ''normal'' scale) is increased by a small factor, f (larger than 1).
Special cases associated with the approach. While the discussion above concerns the general case of the Richards function, some special cases are investigated below. BMDs presented in this study are estimated using these special cases. Considering the Hill function, the BMD T is solved as (for m ¼ 1 in Equation 5):
The response, R T , associated with this exposure is
Thus, considering the symmetrical case of the Hill function, the response associated with the BMD T has a constant value 0.21. Generally, the response (R T ) at the BMD T becomes lower as the m parameter in the Richards function becomes higher, and vice versa. Considering the asymmetrical threshold-like dose-response relationship (m > 1), the Richards function has a limiting case as the m parameter becomes large. If solving for the point of inflection in the Richards function, i.e.,
which is obtained by solving the root of the second derivative, and substitute
, it is possible to see that when m approaches infinity, the Richards function tends to the Gompertz curve,
By repeating the steps previously described for the Richards function, the BMD T according to the Gompertz curve is given by
The Richards function and its second and third derivative. In the example, a ¼ 60, h ¼ ÿ50, j 1 ¼ log 10, g ¼ 2, and m ¼ 2. The BMD T (i.e., log BMD T ) is defined as the dose where the slope of the curve changes the most in the low-dose region. As shown, this dose level corresponds to the dose where the second derivative is the lowest, and where the third derivative equals zero. The response, R T , associated with this dose is 0.15, i.e. according to equation (7) for m ¼ 2.
A CRITICAL DOSE LEVEL FOR RISK ASSESSMENT Thus, considering the symmetrical to the limiting asymmetrical threshold-like case the response (R T ) associated with the BMD T ranges from 21% to 7.3%.
Calculation of confidence interval for the BMD. A confidence interval for the BMD was calculated using a likelihood ratio test statistic. The lower bound, BMDL, of a 95% confidence interval was specified as the BMD that satisfies ÿ2ðln L rep ÿ ln LÞ ¼ v , given a constraint on the BMD. In the latter case, l(d i ) is reparameterized so that the location parameter, j 1 or x 1 (in the Hill function or the Gompertz curve), is expressed in terms of the BMD and other parameters.
Comparison to other procedures for BMD analysis. The suggested procedure for BMD analysis was contrasted to other definitions available for continuous data: the hybrid method (Crump, 1995; Gaylor and Slikker, 1990) and the critical effect size (CES) approach (Slob and Pieters, 1998) . According to the hybrid method, a cut-off value for adverse response is defined. In the present work the cut-off was specified as corresponding to an extreme tail proportion of 0.01 of the estimated control distribution, p(0) ¼ 0.01 (the 1st or 99th percentile). Using this cut-off specification, the additional risk, p(BMD) -p(0), at the BMDs obtained in this study was calculated. Details about the hybrid approach can be found in Sand et al. (2003 and . The CES represents a change in response relative to the background value, CES ¼ jlð0Þ ÿ lðBMDÞj lð0Þ :
The CES associated with the BMDs obtained in this study was also calculated. The performance in confidence interval calculation was compared between the different BMD definitions. The BMDs presented in this study can be obtained by considering the suggested approach (presented later in Table 2 ) or by considering the corresponding settings (for the given data set) under the alternative approaches, i.e., the corresponding additional risk under the hybrid approach (presented later in Table 3 ) or the corresponding CES (presented later in Table 4 ). The width of the confidence interval, and hence the BMDL, may, however, differ, depending on the procedure considered. The location parameter in the Hill function and the Gompertz curve (i.e., j 1 or x i ) can generally be solved as
The Hill function or the Gompertz curve is reparameterized by substituting j 1 or x 1 with Equation 14, given an appropriate formulation for S that depends on the model and procedure selected for BMD analysis. Considering the Hill function and the BMD T definition, S equals S T ¼ 2 þ ffiffi ffi 3 p ; which may be concluded from Equation 8.
If more generally considering a change in response relative to the magnitude of response, i.e., the Murrell et al. (1998) 
where R denotes the response change according to Equation 6. Considering the Hill function and the hybrid method, it can be shown that S equals
where / denotes the standard normal distribution function. The equation above concerns the case of constant variance. BMDL calculation under the hybrid method was performed only for this case, because the case of non-constant variance is not computationally straightforward. Finally, considering the Hill function and the CES approach, S equals
It may be noted that the CES approach coincides with the Murrell et al. (1998) definition-i.e., Equation 6-when h ¼ ÿa, and for this case S CES ¼ S general . All the expressions shown for S can similarly be solved for the Gompertz curve. It appears from the equations that the reparameterized doseresponse model becomes the least complex when defining the BMD under the present definition, or more generally as a change in response relative to the magnitude of response. For these cases, S is a constant. However, considering the hybrid method and the CES approach, S depends on model parameters.
Data material used for illustration and software. For illustration of the proposed method of BMD analysis, previously published data observed in female dioxin-sensitive Long-Evans (L-E) and dioxin-resistant Han/Wistar (H/W) rats following long-term exposure to 2,3,7,8-terachlorodibenzo-p-dioxin (TCDD) were used as the basis (Fletcher et al., 2005; Jämsä et al., 2001; Viluksela et al., 2000) . Data on thymus weight, retinoid parameters, volume fraction of altered hepatic foci, and bone parameters were considered. The doses employed in the studies were 0, 1, 10, 100, and 1000 (H/W only) ng/kg bw/day, and 10 animals were used in each treatment group, except for the data on bone mineral density observed in H/W rats where 5 animals/group were used. The mathematical and statistical procedures required for calculations associated with the present study were implemented in Matlab 7.0.
RESULTS
The symmetrical assumption, represented by the Hill function, as well as an asymmetrical assumption, described by the Gompertz curve, was considered. In Table 1 . Parameter estimates and log-likelihoods associated with the two models are presented for the data used as the basis for illustration of the proposed method of BMD analysis. The parameter estimates for the selected variance models are also given in Table 1 ; the constant variance assumption appeared to be more appropriate, compared to the non-constant model, for the data on thymus weight, hepatic retinyl stearate, and bone mineral density (Table 1) . For all decreasing responses (i.e., the hepatic retinoids and thymus weight), the h parameter in the doseresponse models was restricted to be greater than, or equal to, ÿa to prevent estimated responses from assuming negative values. Considering the different data sets, the log-likelihood associated with the Hill function is generally slightly higher or identical to that associated with the Gompertz curve (Table 1) . Formal comparison between the Hill function and the Gompertz curve cannot be carried out because the models are not nested (even though both models are special cases of the Richards function) and include the same number of parameters. However, it seems that neither model is to be preferred over the other, because only slight differences in model fits were obtained-i.e., the likelihoods in Table 1 . Thus, for the present data material it seems difficult to discriminate between the symmetrical (Hill function) and the asymmetrical (Gompertz curve) assumption. This feature may also be explored visually in Figures 3, 4 , and 5.
The BMD T , with lower bound BMDL T , is presented in Table  2 . In Figure 3 and 4 models fitted to data on volume fraction of hepatic foci (observed in L-E rats) and bone mineral density (observed in H/W rats) are illustrated, respectively. As is shown 244 in the illustrations, the BMD T , and BMDL T , from the Gompertz curve are lower than those for the Hill function. This more conservative behavior of the Gompertz curve was a general observation ( Table 2) . The lower response level (R T ) associated with the BMD T according to the Gompertz curve (i.e., 7.3% vs. 21% according to the Hill function) seems to counteract its more threshold-like characteristics (Figs. 3 and 4) . Differences between the Gompertz curve and the Hill function were assessed in terms of BMD T ratios and BMDL T ratios. The BMD T , and BMDL T , from the two models differed by a factor of 2-4 (Table 2) .
A conservative approach can be applied, given the situation of model uncertainty previously discussed; i.e., assume a limiting case scenario of asymmetry and use the results associated with the Gompertz curve. Alternatively, the response level associated with the extreme case of asymmetry can be used (R ¼ 7.3%), and models other than the Gompertz curve may also be considered for estimation of the corresponding dose. Such a formulation will, in a conservative manner, account for the uncertainties associated with the proposed methodology. Table 2 also present results for the case where the BMD, and its lower bound, BMDL, is defined as corresponding to a 7.3% change in response relative to the magnitude of response, according to the Hill function-i.e., BMD 0.073, Hill with lower bound BMDL 0.073, Hill . In this situation, lower values (BMDs, and BMDLs) are obtained by the Hill function (compared to the Gompertz curve, Table 2), which is related to the less threshold-like characteristics exhibited by this model. This feature is illustrated in Figure 5 using data on hepatic retinyl palmitate observed in H/W rats. Thus, use of the response level associated with the extreme case scenario of asymmetry b For thymus weight, hepatic retinyl stearate, and bone mineral density a constant variance assumption was supported over the non-constant model (a power function of the mean response) according to a likelihood ratio test.
c j 1 is the location parameter in the Hill function, and x 1 is the location parameter in the Gompertz curve.
FIG. 3.
The Hill function and the Gompertz curve fitted to data on volume fraction of hepatic foci observed in Long-Evans rats following long-term exposure to TCDD. The BMD T , with lower bound BMDL T , is defined as the dose where the slope changes the most. The response, R T (defined as a change in response relative to the magnitude, or size, of response), corresponding to the BMD T is approximately 0.21 and 0.073 according to the Hill function and the Gompertz curve, respectively.
A CRITICAL DOSE LEVEL FOR RISK ASSESSMENT appears to be even more conservative than use of the extreme case model itself (Gompertz curve). Model dependence was also investigated at the 7.3% response level (Table 2) . Differences (in terms of BMD ratios) between the Hill function and the Gompertz curve, for this case, were quite similar to those based on the BMD T (and BMDL T ); i.e., the BMD and BMDL from the two models differed by a factor of 1-3.
In summary, the three types of BMDs and BMDLs in Table 2 are consistently ordered in terms of their conservatism; i.e., the BMDL T (and BMD T ) according to the Hill function is higher than the BMDL T (and BMD T ) according to the Gompertz curve, which is higher than the BMDL (and BMD), corresponding to a 7.3% change in response according the Hill function. The least conservative BMDL, i.e., the BMDL T according to the Hill function, is closest to the NOAEL. Only for the data on hepatic retinyl palmitate observed in H/W rats (Fig. 5) are all BMDLs higher than, or in the range of, the NOAEL. It is realized that larger data material would be required to obtain a clearer idea of how the BMDL T relates to the NOAEL. However, this is beyond the scope of the present study.
In Table 3 , the additional risks at the three types of BMDs presented in Table 2 are given. The additional risk at BMDs corresponding to a 7.3% change in response relative to the magnitude of response (i.e., BMD T, Gompertz and BMD 0.073, Hill ) is in the range of 1-10% (Table 3) . However, the additional risk at the BMD T according to the Hill function is generally higher than 10%, except for data on thymus weights and bone mineral density. For hepatic retinyl palmitate and volume fraction of foci observed in L-E rats, the additional risk at BMD T, Hill appears to be rather high; the BMD T approximately corresponds to the ''hybrid'' ED 50 . For these data, the hybrid model may be seen as a ''low-dose model,'' because approximately half the hybrid model is confined between a dose of zero and BMD T, Hill . The results in Table 3 for the Hill function show that the additional risk is more sensitive to dose, in the region considered, compared to the change in response relative to the magnitude of response (R); the additional risk at BMD T, Hill is up to 10 times higher than that at BMD 0.073, Hill while R ranges from 0.21 to 0.073, Table 3 ). Moreover, BMDLs computed under the hybrid method are lower than the corresponding BMDLs estimated under the suggested procedure (Table 3) . This indicates that the definition of the BMD as corresponding to an additional risk may be more uncertain compared to defining the BMD according to the discussed approach (differences between the BMDLs may be considered to be marginal for some of the present data, Table 3 ).
In Table 4 , the CES associated with the three types of BMDs presented in Table 2 are given. As shown, the CES is quite divergent between the different endpoints, which of course should be expected because the backgrounds, a, differ. On some occasions the CES assumes values of 0.21 and 0.073, i.e., the CES approach coincides with, or approximates to, the proposed definitions. This occurs for data where the estimate of h equals, or approximates to (Hill function for hepatic retinyl palmitate observed in H/W rats), ÿa, which can be concluded from Table 1 . Table 4 shows that BMDLs computed under the CES approach are equal to, or lower than the corresponding BMDLs estimated under the proposed definition. The case of equal BMDLs relates to the occasions when the two approaches coincide. However, when this is not the case, Table 4 indicates that the definition of the BMD in terms of a CES may be more uncertain than defining the BMD according to the suggested approach (differences between the BMDLs may be considered to be marginal for some of the present data, Table 4 ).
DISCUSSION
The definition of a point of departure for risk assessment as corresponding to a certain response level has been presented as a major advantage. However, this has also proved to be one of the greatest challenges associated with the BMD concept (Edler et al., 2002) . Considering the various suggestions of how to calculate the BMD for continuous endpoints, it seems still to be a matter of debate which settings (i.e., what response level and/or cut-off criterion) should be used within either of these procedures. The present study has addressed these issues by presenting the BMD as the dose at which the slope of the S-shaped dose-response relationship changes the most in the low-dose region. This approach defines the BMD within a dose region where the sensitivity to chemical exposure may change noticeably, indicating that a fundamental shift in the dose-response curve occurs. Murrell et al. (1998) has previously suggested that a dramatic change in slope may signify something about the biological mechanism, pointing out that the BMD should be defined in a region of nonlinearity. The d Calculation of a BMD, and BMDL, is computationally difficult for data with non-constant variance (see Table 1 ).
e Values in parenthesis are the BMDLs estimated under the proposed definition (presented in Table 2 ), displayed also here for comparative purposes. a Previously published data observed after long-term exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin are used as basis (Viluksela et al., 2000; Jämsä et al., 2001; Fletcher et al., 2005) .
b BMD T, Gompertz , with lower bound BMDL T , is the dose where the slope changes the most according to the Gompertz curve (R T ¼ 0.073). A CRITICAL DOSE LEVEL FOR RISK ASSESSMENT significance of dose-dependent transitions has also more recently been discussed, and it has been argued that consideration of such transitions could improve the risk assessment (Slikker et al., 2004a (Slikker et al., , 2004b . For example, the identification of a transition dose region is suggested to be crucial to properly define the lowest range of doses appropriate for extrapolation, for example between different species. Although this article does not discuss the underlying events that may be responsible for a dose-dependent transition, it does discuss how a BMD may be defined in such a dose region.
As initially pointed out, for BMD calculations from continuous data the ''hybrid approach'' has been suggested. According to this method, besides specifying the benchmark response level, a cut-off level denoting ''adverse'' response must initially be determined (Crump, 1995; Gaylor and Slikker, 1990) . By defining the cut-off as corresponding to the 1st or 99th percentile of the control distribution, the hybrid approach has recently been compared to a case in which the BMD was defined as corresponding to a 1% change in response relative to the magnitude of response (Gaylor and Aylward, 2004) . This latter procedure was called the ''ED 01 '' approach by the authors, and it is equivalent to considering a 1% response change under the Murrell et al. (1998) response definition. Using the Hill function, Gaylor and Aylward (2004) concluded that the hybrid procedure performed better than the ED 01 approach; i.e., the uncertainty associated with BMDs corresponding to additional risks of 1%, 5%, and 10% (estimated using the hybrid approach) was lower than that associated with the ED 01 . These findings were attributed to the fact that a higher degree of extrapolation was associated with the ED 01 approach; i.e., the ED 01 was generally much lower than the BMDs estimated under the hybrid method.
In contrast to the investigation by Gaylor and Aylward (2004) , in the present study comparison was made considering the same point estimate (BMD). Generally speaking, a confidence interval may be expected to become shorter as the slope of the curve at the point estimate becomes higher, everything else being equal (for example, given a certain dose-response model and method of confidence interval calculation). For this reason, the present study considers the same point estimate in this comparison, which seems more relevant if one attempts to generally compare uncertainties inherent in particular BMD definitions. However, the conclusions of Gaylor and Aylward (2004) may not have been intended to generalize beyond the settings applied in their study. According to the present work, indications were made that the definition of the BMD as corresponding to an additional risk (under the hybrid approach) may be more uncertain than defining the BMD according to the suggested procedure, or more generally according to the Murrell et al. (1998) definition (Table 3) .
Considering the procedure of defining the BMD as the dose causing a percentage change in response relative to the background, the appropriate idea of using endpoint-specific response values has been discussed (Slob and Pieters, 1998) . However, consensus regarding such values is generally lacking (Dekkers et al., 2001) . In the early stages of BMD analysis and its application to developmental toxicity, it was observed that the NOAEL, on average, most resembled a BMD corresponding to a 5% change in response relative to background (Allen et al., 1994) . This observation was later used as an argument when applying the 5% response level (Allen et al., 1996 Kavlock et al., 1995) . However, it has been pointed out that the recommendation of certain response levels based on resemblance to the NOAEL may not constitute a scientific rationale for BMR selection, but rather reflects the level of response that has historically been associated with applications of the NOAEL approach (Allen et al., 1994; Barton, and Das, 1996; Setzer, and Kimmel, 2003) . Like the findings for the hybrid approach, this study indicated that the definition of the BMD in terms of a CES may be more uncertain than defining the BMD according to the suggested approach, or more generally according to the Murrell et al. (1998) definition (Table 4) . These results (Tables 3 and 4) may be associated in part with the fact that the reparameterized model, used for confidence interval calculation, becomes quite simple under the suggested procedure for BMD analysis (see Material and Methods). While differences between the discussed methods, in terms of the uncertainty in the BMD, may become ''significant,'' it should perhaps be kept in mind that the choice of dose-response model also represents a source of uncertainty (Tables 2, 3 , and 4).
The suggestion in this study to define the BMD as the dose at which the slope of the dose-response relationship starts to change noticeably may in part be seen as a contribution to biologically based procedures for BMD analysis. The proposed BMD denotes a form of change point, and the region where a fundamental shift occurs in the dose-response relationship may also relate to the concept of a threshold dose. This latter feature has been discussed by Dybing et al. (2002) , who argue that a biological threshold represents a certain dose region where a substantial change in response occurs, rather than a single dose level. Moreover, the present definition of the BMD provides means of by passing problems associated with other procedures of BMD analysis; problems of specifying endpoint-specific values of the critical effect size (CES), or problems related to the selection of a cut-off value, a BMR, and an appropriate variance model in the context of the hybrid approach. The procedure discussed in this study indirectly suggests the response associated with the BMD; both the degree of exposure and the response reside within the proposed definition.
In this study the Richards function was considered as a general model for the S-shaped dose-response relationship. It can be shown that several of the sigmoidal dose-response models that exist are, in fact, special cases of the Richards function, including the Hill function, the Michaelis-Menten equation, and the Gompertz curve (Giraldo et al., 2002) . The Hill function (Cornish-Bowden, 1995) is perhaps the most commonly used dose-response model in pharmacology, and it has also been acknowledged in applications relating to risk assessment of chemicals and BMD analysis (Barton et al., 1998; Murrell et al., 1998; Kim et al., 2002; Gaylor, and Aylward, 2004; Sand et al., 2004; Toyoshiba et al., 2004; USEPA, 2005 ). An exponential family of models that has been suggested by Slob (2002) may also be considered to be a special case of the Richards function.
It was shown that the response, R T (defined as a change in response relative to the magnitude, or size, of response), associated with dose where the slope changes the most depends on the geometrical shape of the dose-response curve; the response (R T ) becomes lower as the curve becomes more asymmetrical and threshold-like in the low-dose region. According to the limiting case of the Richards function-i.e., the Gompertz curve-the response (R T ) corresponding to the BMD T becomes as low as 7.3%. Use of this response level when estimating the BMD conservatively accounts for uncertainties associated with the proposed methodology (information about the geometrical shape of the dose-response curve may generally be lacking). At the 7.3% level, different S-shaped models should generally perform conservatively when compared to the Gompertz curve, because they are less asymmetrical, as was shown for the Hill function in the present study (Table 2, Fig. 5) . Also, for dose-response relationships that are less threshold-like than the Gompertz curve, the 7.3% response level may be seen as corresponding to a dose level in a more conservative part of a transition dose region. With all else being equal, a transition dose region may be regarded to be wider and less clearly defined as the m parameter in the Richards function decreases, i.e., as the curve becomes less Gompertz-like (Fig. 1) , and at some point BMD T may be associated with ''adverse effects'' (R T may be large for small values of m, Equation 7).
For the proposed definition of the BMD, it is important that the full S-shaped dose-response curve can be estimated accurately; it is of interest to also include high-dose levels in the experiment so that information about the maximum or minimum response level is obtained. In the field of BMD modeling, observations in the low-dose region have been considered to have more merit than those in the high-dose region (USEPA, 1995), which apparently does not apply for a quantity as the BMD T . However, a recent simulation study investigating study designs appropriate for BMD estimation indicated that consideration of the high-dose region is also important when estimating a BMD corresponding to a percent change in response relative to background, i.e., corresponding to a CES of 5% (Slob et al., 2005) . While the present study discusses how a BMD may be defined in a transition dose range using the full S-shaped curve, a future prospect concerns how this may be achieved using a simpler dose-response model. Considering the ''normal'' dose scale, the outlined concept may also be applicable as long as the dose-response is S-shaped (on ''normal'' dose scale). However, because of differences in the interpretation of slope on the ''normal'' dose scale vs. the log-dose scale a BMD T may not be independent on the dose scale considered. Also, while not discussed, the suggested procedure may also be applicable to quantal data.
CONCLUSIONS
In the present study, developments in BMD analysis of continuous experimental data have been discussed. It was proposed that the BMD can be defined as the dose at which the slope of the S-shaped dose-response curve changes the most in the low-dose region; this dose resides in a transition dose range where the sensitivity to chemical exposure may change noticeably. As has been shown, this definition of the A CRITICAL DOSE LEVEL FOR RISK ASSESSMENT
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BMD indirectly suggests what specific response(s) it should be associated with. Considering a limiting case of asymmetry and threshold-like characteristics, reflected by a Gompertz curve, the response corresponding to the dose of interest becomes as low as 7.3% (defined as a percent change in response relative to the magnitude of response). Thus, the use of a response (R) in the range of 5-10% conservatively accounts for uncertainties associated with the proposed strategy of defining the BMD and its lower bound (BMDL) in a transition dose region, and it may be appropriate from a regulatory point of view. The present investigation also indicated that a BMD defined according to the suggestion may be estimated more precisely relative to BMDs defined under the hybrid method and the CES approach, given the S-shaped dose-response models considered.
